<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00852020</url>
  </required_header>
  <id_info>
    <org_study_id>PCSU-002-CFS</org_study_id>
    <nct_id>NCT00852020</nct_id>
  </id_info>
  <brief_title>Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Chronic Heart Failure and Chronic Obstructive Pulmonary Disease Patients</brief_title>
  <official_title>Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in CHF and COPD Patients. A Randomised, Double-blind and Controlled Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Kabi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Kabi</source>
  <brief_summary>
    <textblock>
      To test the compliance, tolerance, safety and to get preliminary insights into the efficacy
      of a new oral nutritional supplement (containing n-3 fatty acids, amino acids and
      antioxidants) designed to prevent or delay cachexia and anorexia in patients with chronic
      heart failure (CHF) or chronic obstructive pulmonary disease (COPD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>compliance to nutrition therapy</measure>
    <time_frame>baseline, months 1, 2, 3, 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>anorexia questionnaire</measure>
    <time_frame>baseline, months 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal syndrome score (GIS)</measure>
    <time_frame>baseline, months 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body cell mass</measure>
    <time_frame>baseline, months 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>weight change</measure>
    <time_frame>baseline, months 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hand grip strength</measure>
    <time_frame>baseline, months 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient global assessment (PGA)</measure>
    <time_frame>baseline, months 2, 4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Cachexia</condition>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral nutritional supplement containing n-3-fatty acids, amino acids and antioxidants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral nutritional supplement (isocaloric, isonitrogenous)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>oral nutrition supplement, food for special medical purposes</intervention_name>
    <description>2 servings of 200-300 ml per day, treatment period: 16 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of CHF or COPD

          -  current body weight less than 6 months ago

          -  BMI &gt;=20 and &lt;=30 kg/m2

          -  CHF: LVEF &gt;=45% measured within the past 6 months

          -  symptom status equivalent to NYHA class II to IV

          -  biochemical abnormalities for total cholesterol, serum uric acid, abnormal high CRP

          -  on standard therapy of CHF including ACE inhibitors and beta blockers

          -  COPD: symptom status equivalent to GOLD standard class II to IV

          -  FEV1 &lt; 80%

          -  FEV1/FEV &lt; 70%

        Exclusion Criteria:

          -  significant oedema in the time of screening and randomisation

          -  concomitant inflammatory diseases

          -  active infections including HIV and AIDS

          -  liver failure

          -  chronic renal failure (sCr&gt;1.5mg/dL) or cardiac pacemaker

          -  acute or chronic infections

          -  insulin treated diabetes mellitus

          -  patient with established diagnosis of cachexia

          -  life expectancy of less than 6 months in the opinion of the investigator

          -  medications that impair sex hormone synthesis, secretion or function

          -  patients with psychiatric diseases

          -  body weight loss &gt; 5% during the last 6 months or &gt; 10% during the last 10 months

          -  suspected allergy to any component of the investigational product(s)

          -  fish oil supplementation within 3 months prior to the study entry

          -  taking vitamin supplements in doses greater than the Recommended Daily Allowances
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Anker, Prof. MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center of Cachexia Research, Department of Cardiology, Charité Campus Virchow-Klinikum, Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center of Cachexia Research, Department of Cardiology, Charité, Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>D-13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Pneumologie, Schwedt/Oder</name>
      <address>
        <city>Schwedt/Oder</city>
        <zip>D-16303</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionalne Centrum Leczenia Chorób Płuc i Alergii, NZOZ ALLMED</name>
      <address>
        <city>Piekary Śląskie</city>
        <zip>PL-41-940</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalista Chorób Wewnętrznych Kardiolog</name>
      <address>
        <city>Ruda Śląska</city>
        <zip>PL-41-709</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2009</study_first_submitted>
  <study_first_submitted_qc>February 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2009</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

